David Andorsky, MD
Hematology & Oncology · Boulder, CONPI 1609061837
Payments from drug & device makers
Across 645 payments — averaging $48,812 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$27.8M
- Epizyme, Inc.$834K
- AbbVie$770K
- Bristol Myers Squibb$543K
- E.r. Squibb & Sons, L.L.C.$315K
- Merck$275K
- plus $920K from 19 others
Across 37 payments — averaging $3061.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$63K
- Novartis Pharma AG$15K
- Novartis$12K
- Acerta Pharma LLC$8K
- F. Hoffmann-la Roche AG$6K
- Bristol Myers Squibb$6K
- plus $4K from 3 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 30 | $27,827,449 |
| Epizyme, Inc. | 189 | $833,847 |
| AbbVie | 51 | $769,598 |
| Bristol Myers Squibb | 21 | $542,670 |
| E.r. Squibb & Sons, L.L.C. | 23 | $315,054 |
| Merck | 1 | $275,000 |
| Genentech, Inc. | 37 | $234,590 |
| TG Therapeutics, Inc. | 67 | $152,658 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $149,207 |
| AstraZeneca(2 entities) | 17 | $127,183 |
| Incyte Corporation | 133 | $98,422 |
| Acerta Pharma LLC | 5 | $77,300 |
| CTI Biopharma Corp. | 2 | $59,960 |
| Janssen Research & Development, LLC | 12 | $6,570 |
| Verastem, Inc. | 3 | $6,500 |
| Blueprint Medicines Corporation | 3 | $2,805 |
| F. Hoffmann-la Roche AG | 1 | $2,280 |
| Ipsen Bioscience Inc. | 1 | $1,230 |
| Genmab U.S., Inc. | 2 | $1,040 |
| Karyopharm Therapeutics Inc. | 1 | $51 |
| Telix Pharmaceuticals | 2 | $34 |
| Johnson & Johnson | 1 | $26 |
| Myriad Genetic Laboratories, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Gilead | 1 | $12 |
How this compares
$31,483,522 in reported general payments places this provider in the 95th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Boulder
- Jenny FoxBoulder$4.7M
- Lori JensenBoulder$356K
- John BurkeAurora$25.4M
- Elena ShagisultanovaAurora$22.4M
- Allen CohnDenver$13.5M
- Elaine LamAurora$12.6M
- Robert RifkinDenver$11.3M
- Robert JotteLone Tree$9.4M
- Daniel PollyeaAurora$9.4M
- Henning SchadeDenver$9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.